The total Familial chylomicronemia syndrome prevalent population in the 7MM (the US, EU5 (the UK, Germany, France, Spain, and Italy) and Japan) was assessed to be 5,801 in 2017.
The current Familial Chylomicronemia Syndrome market is mainly dominated by traditional TG-lowering agents, and as per DelveInsight analysis, the market worth was estimated to be USD 1.0 million in 2017.
Some of the leading pharma players working towards the development of better treatment approaches for FCS patients include Akcea Therapeutics, Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Amryt Pharma plc and others.
For more details visit: https://www.delveinsight.com/blog/familial-chylomicronemia-syndrome-market/